Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 10Carcinoma, Ovarian Epithelial 4Fallopian Tube Neoplasms 3Peritoneal Neoplasms 1Neoplasms 1Adenocarcinoma 1

Interventions

Gemcitabine 22Fluorouracil 14Oxaliplatin 13Capecitabine 13Paclitaxel 12pembrolizumab 11Cisplatin 11Carboplatin 11Pemetrexed 10Leucovorin 9130-nm albumin-bound paclitaxel 9Ramucirumab 8zolbetuximab 7Albumin-Bound Paclitaxel 7trastuzumab deruxtecan 6Drug Therapy 5Docetaxel 5Bevacizumab 5Nivolumab 4Irinotecan 4vandetanib 3cemiplimab 3Everolimus 3EC145 3tislelizumab 2technetium 99m etarfolatide 2spartalizumab 2pralsetinib 2osimertinib 2nimotuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma × oregovomab × Clear all
NCT01616303 2020-09-14

A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer

Quest PharmaTech Inc.

Phase 2 Completed
97 enrolled
Gynecologic

Adenocarcinoma, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡